Jinan Hongyuan Chemical Co.,Ltd

Jinan Hongyuan Chemical Co.,Ltd

info@hychem-china.com

86-13954187575

Jinan Hongyuan Chemical Co.,Ltd
Casa> Blog> The new drug is derailed! Top 10 drug distribution

The new drug is derailed! Top 10 drug distribution

November 02, 2021

Best or Worst, the true success of a new drug depends on its commercial potential. The approval of the drug regulatory agency is only the beginning. After the approval, the full use of the commercial potential can ensure that its manufacturers can recover R&D costs, provide funds for future drug discovery, and meet the needs of investors with substantial profits. This is the key to the survival of the drug life cycle. Sexual step. According to a previous report from LEK Consulting, among the 450 new molecular entities that were approved by the FDA between 2004 and 2016, about 40% of the products had post-market sales that were lower than expected by more than 20%. Recently, Fierce Pharma sorted out the top 10 most failing drugs after being launched in the past 5 years. Including drugs whose sales are not as good as expected, or whose sales are stable, but still encounter major setbacks, which have raised doubts about their long-term commercial value. TOP10 medicines cover multiple fields such as oncology, immunology, infectious diseases, ophthalmology, blood diseases, brain diseases, and cardiovascular and metabolic diseases. It involves pharmaceutical giants such as Pfizer, Novartis, and Eli Lilly, as well as biotech start-up companies such as Amarin and Bluebird Bio.It is worth mentioning that with the exception of Amarin's Vascepa, the rest of the drugs are all start-up drugs. TOP 10 "Most Failed" New Drugs on the Market




Serious security issues "blockbuster" becomes "thunder bomb"?



It was launched with great expectations, but there were problems in the safety assessment after the market, which dealt a fatal blow to the launch of new drugs, such as Novartis`s Beovu, Sanofi`s Dengvaxia, and Arcadia`s Nuplazid after the approval of safety issues; Originally expected blockbuster drugs have become "duds", and sales performance is far less than expected.


Novartis: Beovu


Beovu is a new generation of anti-vascular endothelial growth factor (VEGF) drug developed by Novartis Pharmaceuticals. It was approved by the FDA for priority review in October 2019 for the treatment of wet-AMD (also known as neovascularization). Sexual AMD, nAMD). Prior to its launch, the market has always been optimistic about Eylea (aflibercept), a blockbuster ophthalmic product comparable to Regeneron, and believes that it is expected to break the status of replacing Eylea's global best-selling drug and become an anti-VEGF drug with better performance in reducing retinal fluid. However, due to its serious side effects, vasculitis and other complications that may cause vision loss, it was given a black box warning by the US FDA in April 2020. In addition, in June of this year, due to safety frustrations, the incidence of intraocular inflammation in Beovu doubled compared with patients receiving aflibercept treatment, and Novartis stopped three clinical trials of Beovu ahead of schedule. Greatly reduced Beovu's market penetration rate. Previously, Wall Street analysts predicted that Novartis' new eye medicine would top the market in 2026; revenue is expected to be approximately US$4.38 billion by the end of 2021. However, the financial report shows that the sales of Beovu in 2020 are only 190 million US dollars, and the sales of 2021 Q1 Beovu only realized 39 million US dollars, which is a decrease of 44% from the previous year (the sales so far in 2021 are only 87 million US dollars , A decrease of 16% compared to the same period last year); In contrast, Aflibercept`s sales in the United States during the same period increased by 15% to 1.35 billion US dollars.



Sanofi: Dengvaxia


Dengvaxia is the world's first and only currently marketed dengue vaccine developed by Sanofi at a cost of 1.5 billion euros and 20 years of research and development. Once considered to be another blockbuster product of Sanofi; never thought it became a "thunder bomb." According to the follow-up data of the Dengvaxia clinical trial published by Sanofi, the vaccine works as expected for people who have been exposed to dengue virus; however, for patients who have not previously been infected with dengue fever, vaccination may cause severe illness and even shock. Syndrome and died. And the Philippines canceled the vaccination plan and charged Sanofi with a refund. So far, Dengvaxia has been put into the cold palace, and sales data for 2020 has not been disclosed.


Arcadia: Nuplazid


Nuplazid is an inverse agonist that targets the serotonin 2A receptor (5-HT2A) developed by Acadia. It is currently the only drug approved by the FDA for the treatment of hallucinations or delusions caused by Parkinson's disease. Known as a blockbuster with a potential of $1 billion. However, Nuplazid has been controversial since it was approved in 2016, and it was able to go on the market thanks to the lack of new drugs for this indication. According to ISMP statistics in November 2017, a total of 244 patients who took Nuplazid died from the launch of Nuplazid to 2017. In April 2018, CNN reported that hundreds of PD patients died after taking Nuplazid. CNN suspected that the patient had a safety accident and Nuplazid. Inevitably, Acadia's stock price fell by 20% that day. In addition, in July 2019, Nuplazid studied ENHANCE's phase III clinical failure of schizophrenia, which raised questions about its scope of activity. In April of this year, the FDA rejected its complementary new drug application (sNDA) for the treatment of hallucinations and delusions associated with dementia-related psychosis (DRP).Sales in 2020 are only US$441.8 million, which is far less than expected.



Differentiated advantages are not obvious and are crushed by competing products


If you can't be the first person to eat crabs, then the successor must have a prominent advantage in order to shine on the Nuggets track. However, Clovis Oncology's Rubraca in the field of PARP inhibitors, and Merck and Pfizer's Steglatro in the field of SGLT2 do not have obvious differentiation advantages. They have not been able to surpass the former and have been chased by latecomers.


Pfizer: Eucrisa


Eucrisa is a non-steroidal in vitro PDE4 inhibitor. It was the core product that Pfizer bought when Anacor Pharmaceuticals was purchased for US$5.2 billion in 2016. It was approved by the FDA for the treatment of atopic dermatitis in the same year. Pfizer once believed that its Eucrisa sales peak could reach or exceed US$2 billion. However, he never expected to be oppressed by the Dupixent antibody injections of Sanofi and Regeneron, which were approved three months later. Dupixent is now recognized as the first choice for eczema. And Eucrisa's main sales growth window is rapidly closing. For the whole year of 2019, Eucrisa's sales were only 138 million U.S. dollars, lower than the 147 million U.S. dollars in the previous year. At the same time, more new competitors are also accelerating the disintegration of Pfizer`s Eucrisa specific dermatitis market, such as Opzelura, the first and only JAK inhibitor Incyte, which has just been approved by the FDA; and the same PDE4 inhibitor. Arcutis Biotherapeutics' ARQ-151 is currently in clinical phase 3.


Clovis Oncology: Rubraca


Rubraca is an oral, small molecule poly ADP ribose polymerase (PARP) inhibitor. It is the second PARP inhibitor to be marketed in the United States after AstraZeneca Lynparza in 2014. The FDA has granted Rubraca priority review and breakthrough drug treatment qualifications, and has also obtained orphan drug designation. Analysts had predicted that Rubraca's sales in 2021 may reach 663 million U.S. dollars. However, in the first half of 2021, Rubraca's sales were only $74.9 million. In contrast, Lynparza had sales of $1.13 billion during the same period. At the same time, with the rapid development of the PARP inhibitor market, the advantages of Rubraca have lost attention in the brilliance of competing products, Merck & Co. Zejula and AstraZeneca`s Lynparza, and maintenance therapy has become the standard therapy for patients with advanced ovarian cancer. Zejula and Lynparza seized the first-mover advantage; in addition, GlaxoSmithKline and Pfizer Research and invest in other PARP inhibitors are also following, and Rubraca's later commercial road is more difficult.


Merck/Pfizer: Steglatro


Steglatro is a sodium-glucose cotransporter-2 (SGLT-2) inhibitor. It was jointly developed by Merck and Pfizer. It was approved by the FDA in 2017 for use in patients with type 2 diabetes who still have poor blood sugar control through exercise and diet. As we all know, the type 2 diabetes drug market has always been a mature and crowded track. Before Steglatro was approved, other SGLT2 therapeutic drugs such as Johnson & Johnson's Invokana, AstraZeneca's Farxiga and Boehringer Ingelheim, and Eli Lilly's Jardiance had entered the market. , And has matured commercialization. These drugs reached a total sales of US$6.15 billion in 2020, and Steglatro, which is expected to sell US$1.09 billion in 2022, has not disclosed its performance in 2020, which means that it is not satisfactory. Merck and Pfizer tried to differentiate themselves through price competition. Steglatro and its Segluromet combination were priced at $8.94/day, while Jardiance was $13/day, and Farxiga was $11.57/day. The advantages were not obvious. In addition, Steglatro missed all secondary endpoints in the Vertis CV trial. The drug did not prolong the time of cardiovascular death or hospitalization due to heart failure, nor did it prevent kidney problems. It again lags behind similar products such as Johnson & Johnson and AstraZeneca.


Amarin: Vascepa


Vascepa is often referred to as fish oil medicine for short. It is a single-molecule prescription product derived from fish and produced through a complex process. It is composed of omega-3 fatty acids in the form of ethyl esters (usually called EPA). It is a new FDA-approved product. Chemical entities. It was first approved in 2012 for lowering triglyceride levels. After 7 years, it was approved to reduce cardiovascular risk in December 2019. Hope to usher in a new growth point of performance. But after the seemingly transformative approval will become the new engine of performance; Vascepa was ruled by the U.S. District Court of Nevada that its key patent was invalid, although Amarin argued that the significant efficacy shown by the REDUCE-IT clinical study proved the rationality of the patent. However, the court did not buy it. And with the failure of the appeal, Amarin is in crisis, and generic drugs are approaching. The Vascepa generic drug launched by London-based Hikma was approved by the FDA in May 2020. Leerink analysts estimate that Vascepa's sales may fall by 6% to 22% by 2023, depending on the success of Amarin's new strategy and the degree of generic competition that Vascepa will face in the United States.


Expansion of indications meets obstacles, limited market expansion


Although after the listing, objective sales performance was achieved in stages. However, the market for a single indication is limited after all. Only by continuously stimulating the potential and expanding new indications can it become more popular. Lilly's Lartruvo and Intercept's Ocaliva were hit by waterloo due to failure to expand their indications.


Eli Lilly: Lartruvo


Lartruvo is a human IgG1 monoclonal antibody with high targeting affinity for human platelet-derived growth factor receptor-α (PDGFRα). Lartruvo was developed by Eli Lilly and was approved by the FDA in October 2016. It is the first first-line soft tissue sarcoma drug approved by the FDA in 40 years. After listing, Lartruvo has always had good sales performance. According to public data, in the first year of listing, Lartruvo's sales reached 203 million US dollars. In 2018, sales were 304.7 million U.S. dollars. In 2019, analysts forecast Lartruvo's sales to 374.5 million U.S. dollars. However, in a large phase III clinical trial code-named ANNOUNCE, the results showed that patients may have no effect after using Lartruvo. Subsequently, the FDA and the European Medicines Agency recommended that Lartruvo be discontinued in view of the data from this Phase III clinical trial; in April 2019, Eli Lilly withdrew it from the global market and formally applied to the FDA to withdraw Lartruvo in September of the same year. In addition, the FDA withdrew its approval on February 25, 2020. The star anti-cancer drug Lartruvo, which has been waiting for 40 years, is so yellow.


Intercept: Ocaliva


Ocaliva (obeticholic acid, OCA) is an innovative drug farnesoid X receptor (FXR) agonist developed by Intercept, which is a human bile acid mimic. In 2016, it was approved by the FDA for accelerated listing for use in patients with primary biliary cholangitis (PBC). However, in terms of expanded indications, Ocaliva is the only experimental drug that has been granted the FDA breakthrough drug qualification for the treatment of NASH with fibrosis. After obtaining phase III clinical data, the FDA has postponed the review of NASH drugs many times. It is determined that the benefits given to patients after taking the drug can withstand the risks, which brings Intercept back to the design stage. The FDA`s refusal directly blocked Ocaliva`s market expansion. It was originally thought to be able to reach at least 1.6 billion U.S. dollars, with a peak sales of 8.6 billion U.S. dollars, and only generated 313 million U.S. dollars in revenue in 2020.


Misestimating the market, high pricing, discounting the market


Drug developers often get into trouble because they fail to obtain a favorable reimbursement status or miscalculate the market`s acceptance of new products. Bluebird creatures are typical. Because its expensive gene therapy Zynteglo failed to gain coverage in Europe, it recently transformed from a commercial company to a clinical-stage biotechnology company.


Bluebird Creature: Zynteglo


Zynteglo is a Gene therapy designed to treat the blood disease β-thalassemia was approved by the EMA conditionally for marketing in May 2019; however, in order to improve its drug specifications and manufacturing process, Bluebird Bio delayed its launch to 2020; later encountered In the new crown epidemic, the first patient was successfully injected in February this year. In view of the market potential of beta thalassemia and sickle cell disease, Evaluate Pharma at the beginning of 2019 listed Zynteglo as one of the most valuable drug releases of the year, with estimated sales of $1.87 billion in 2024. However, the road to launch is full of obstacles. In the same month that Zynteglo was vaccinated for the first patient, there were cases of blood cancer in Lenti Globin's clinical study for sickle cell anemia (SCD); Bluebird was forced to suspend Lenti Globin's clinical study and Zynteglo's sales. After data analysis and review, it was concluded that Zynteglo's benefits outweighed the risks, and Zynteglo resumed its market sales in July. In addition, Zynteglo has a European price tag of 1.575 million euros (approximately US$1.83 million), making it the world's second most expensive drug after Novartis' gene therapy for spinal muscular atrophy Zolgensma. The high price has once again caused controversy. And failed to reach an agreement with the European government on the price of Zynteglo, leading to its company withdrawing it from the EU market; at the same time, there is news that Bluebird Bio will also withdraw Zynteglo's application for listing in the UK. In this way, Zynteglo's road to launch is still a long way to go, and it is impossible to give high profit returns in the short term. In addition, some analysts believe that if Bluebird reduces the cost of the therapy in Europe, then the charges in the United States must also be lowered. As a result, the entire charge standard in the field of gene therapy will also face collapse. This should be an important reason for Bluebird Bio's withdrawal from the EU market.

Entre em contato conosco

Author:

Ms. Yi

Phone/WhatsApp:

+8618888297294

Produtos populares
Notícias
Notícias da Indústria
You may also like
Related Categories

Enviar e-mail para este fornecedor

Assunto:
E-mail:
mensagem:

Your message must be betwwen 20-8000 characters

Casa

Product

Whatsapp

Sobre nós

Inquérito

We will contact you immediately

Fill in more information so that we can get in touch with you faster

Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.

enviar